Antibody license.

Agensys Inc., a Santa Monica-based biotech bi·o·tech
n. Informal
Biotechnology.

biotech
Noun

short for biotechnology

Noun 1. company, announced a licensing agreement with a potential value of $200 million. The deal centers on an antibody antibody, protein produced by the immune system (see immunity) in response to the presence in the body of antigens: foreign proteins or polysaccharides such as bacteria, bacterial toxins, viruses, or other cells or proteins. to treat prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. . Merck Merck may refer to:

Merck & Co., Inc. ( MSD, Merck Sharp & Dohme outside of the United States and Canada), the USA pharmaceutical company created from assets forfeited after World War I by:

& Co. will pay Agensys $17.5 million immediately and $11.5 million over the next 12 months, subject to certain events. The successful launch of the antibody could trigger milestone payments of $95 million, which could increase to more than $170 million if the drug is approved for more than one type of cancer.

COPYRIGHT 2005 CBJ, L.P.
No portion of this article can be reproduced without the express written permission from the copyright holder.

Reader Opinion

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:	Agensys Inc., Merck and Company Inc. signed an agreement
Publication:	Los Angeles Business Journal
Article Type:	Brief Article
Geographic Code:	1USA
Date:	Oct 24, 2005
Words:	83
Previous Article:	DreamWorks update.(NBC Universal Inc. acquires the assets)(Brief Article)
Next Article:	Gas update.(gasoline prices)(Brief Article)
Topics:	Biotechnology industries Licensing agreements Biotechnology industry Licensing agreements Pharmaceutical industry Licensing agreements

Related Articles
Engineered for Success.(Agensys Inc and Donald B Rice)
BRIEFCASE COURT GIVES OK FOR NET SERVICE.(Business)
Biotech firm raises $42.8 million. (Up Front).(Agensys Inc.)(Brief Article)(Statistical Data Included)
CAMBRIDGE ANTIBODY TECHNOLOGY/AMGEN RESTRUCTURE AGREEMENT.
CRUCELL LICENSES PER.C6 TECHNOLOGY TO GLAXOSMITHKLINE.
CRUCELL/DSM SIGN LICENSING PACT WITH MITSUBISHI PHARMA.
Agensys Signs Collaborative Research and License Agreement With sanofi pasteur.
Abgenix takeover gives Amgen grasp of the humanized mouse.
Biotech/biomed companies: ranked by total employment.(HEALTH CARE)(Company rankings)
Co-development agreement.(HEALTH CARE & BIOTECH)(Agensys Inc. contracts with Seattle Genetics Inc)(Brief article)